Aarti Drugs Limited on Monday announced the financial results of the quarter ended June 2020. The company recorded consolidated quarterly revenue of Rs544.67cr with yoy increase of 34.34%. API segment contributed approximately 85% and formulation around 15% of the total consolidated revenues.
Domestic sales of the API segment grew by ~28.19% and exports by 29.13%. Around 50% of the yoy growth in the API segment was due to volume growth. Formulation segment revenues grew by around 89.49% on a year-on-year basis on the account of high export growth.
Consolidated EBITDA for the quarter ended June 2020 stood at Rs135.23cr, up by 146.89% and consolidated profit after tax for the quarter ended June 2020 was Rs85.45cr, up by 280.63% yoy. Consolidated EBITDA margin improved to 24.83%.
“Despite challenges faced during Covid-19 lockdown, the company was able to maintain good operational efficiency which along with good realization in selling prices led to increased gross margins. Debt/Equity ratio of the Company reduced further down to 0.55 as of June’2020 on a consolidated basis,” company said.
The company has already scaled up its anti-diabetic and anti-inflammatory capacity and it will give impetus to revenue growth in FY21. This would be further supported by good growth in formulation exports.
